Joel T. Wu, JD, MPH, MA and Jennifer B. McCormick, PhD, MPP
False health-related speech can cause harm, but it’s not restricted unless it’s obscene. Physicians are obliged not only to correct patients’ false beliefs, but to engage digital spaces in which false claims thrive.
AMA J Ethics. 2018;20(11):E1052-1058. doi:
10.1001/amajethics.2018.1052.
Government can regulate false speech and professional speech, which bans “gag laws” and compelled speech about laws to restrict abortion, for example. How should health professions share regulatory responsibility with government to prevent true speech about health information from being stifled?
AMA J Ethics. 2018;20(11):E1041-1048. doi:
10.1001/amajethics.2018.1041.
Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
The DSM-5 Task Force’s handling of the ethical controversy over the bereavement exclusion demonstrates the need for more inclusive deliberative processes.
AMA J Ethics. 2017;19(2):192-198. doi:
10.1001/journalofethics.2017.19.2.pfor2-1702.
Michael Anderson, PhD and Susan Leigh Anderson, PhD
Two concerns (unknowability of how output is derived from input and overreliance on clinical decision support systems) are main sources of ethical questions about AI in health care.
AMA J Ethics. 2019;21(2):E125-130. doi:
10.1001/amajethics.2019.125.
Dr Jing Li joins Ethics Talk to discuss her article, coauthored with Dr Robert Tyler Braun, Sophia Kakarala, and Dr Holly G. Prigerson: “How Should Cost-Informed Goals of Care Decisions Be Facilitated at Life’s End?”